Please ensure Javascript is enabled for purposes of website accessibility
Eric Ho

Eric Ho


Pharmacist turned technology executive, serial long in biotechnology, healthcare, and life sciences.

Recent articles

Insurance Ups and Downs for Diabetes Drugs in 2014

Managed care titans CVS Caremark and Express Scripts are undertaking major changes to their preferred drug formularies that may significantly impact a number of well-known diabetes medications and manufacturers.

Zogenix, Zohydro ER Face Familiar Post-Approval Hurdles

In a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...

Payor Trouble for Advair, GlaxoSmithKline Drugs in 2014

A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1.

Rite Aid, Walgreen, and CVS: Can In-Store Care Push Pharmacy Stocks Forward?

The tide has turned dramatically for in-store care clinics at major pharmacy retailers over the last few years. While previously growth for these services had stalled due to lack of dialogue between providers, new waves of partnerships for CVS, Walgreen, and Rite Aid are changing the game for convenient care.

The Weight Loss Drug Company Investors Need to Watch Out For

Big names like GlaxoSmithKline, Arena, VIVUS, and Orexigen are probably well-known among obesity market watchers, but this less publicized company out of Massachusetts is poised to change the landscape in coming years.

CVS Caremark's Big Thanksgiving Purchase: The Coram Buyout

The oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.

The Good News, Bad News for Belviq: …Now the Good News

While Arena Pharmaceuticals' Belviq may need time to gain traction, it may have many of the right pieces in the right places to realize its long-term prospects

The Good News, Bad News for Belviq: Bad News First…

Arena Pharmaceuticals' Belviq continues to stall despite huge early expectations. Let's take a look at the current barriers and potential future success for Belviq...

Eteplirsen in Question: Hope for Sarepta

Recent decisions by the Food and Drug Administration poses new questions about Sarepta Therapeutics, eteplirsen, and the future of DMD treatment.

Pain and Abuse: The Challenge in Bringing Zohydro to Market

Recent developments in controlled substance rules may help Zogenix's extended-release hydrocodone product to market when it will need all the help it can get.

Walgreen and the Biggest Biotech Startup You've Never Heard Of

Walgreen's new partnership could change the way we think of pharmacies.

The Clinical Lowdown: Keryx and Zerenex

A second opinion on the recent Keryx rush.

MannKind Bulls Should Prepare for the Long Haul

Afrezza could be a blockbuster, but will physicians wait and see?